Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome
Authors
Salles, Évila LopesKhodadadi, Hesam
Jarrahi, Abbas
Ahluwalia, Meenakshi
Paffaro Jr, Valdemar Antonio
Costigliola, Vincenzo
Yu, Jack C.
Hess, David C.
Dhandapani, Krishnan M.
Baban, Babak
Issue Date
2020-08-28
Metadata
Show full item recordAbstract
Considering lack of target-specific antiviral treatment and vaccination for COVID-19, it is absolutely exigent to have an effective therapeutic modality to reduce hospitalization and mortality rate as well as to improve COVID-19-infected patient outcomes. In a follow-up study to our recent findings indicating the potential of Cannabidiol (CBD) in the treatment of acute respiratory distress syndrome (ARDS), here we show for the first time that CBD may ameliorate the symptoms of ARDS through up-regulation of apelin, a peptide with significant role in the central and peripheral regulation of immunity, CNS, metabolic and cardiovascular system. By administering intranasal Poly (I:C), a synthetic viral dsRNA, while we were able to mimic the symptoms of ARDS in a murine model, interestingly, there was a significant decrease in the expression of apelin in both blood and lung tissues. CBD treatment was able to reverse the symptoms of ARDS towards a normal level. Importantly, CBD treatment increased the apelin expression significantly, suggesting a potential crosstalk between apelinergic system and CBD may be the therapeutic target in the treatment of inflammatory diseases such as COVID-19 and many other pathologic conditions.Affiliation
Department of Oral Biology and Diagnostic Sciences; Center for Excellence in Research, Scholarship and Innovation; Department of Neurosurgery; Department of Pathology; Children's Hospital of Georgia and Medical College of Georgia; Department of Neurologyae974a485f413a2113503eed53cd6c53
10.1111/jcmm.15883